Novartis goes public with fraud dismissal

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Science Studies Goes Public

I believe that tenured historians, philosophers, and sociologists of science— when presented with the opportunity—have a professional obligation to get involved in public controversies over what should count as science. I stress ‘tenured’ because the involved academics need to be materially protected from the consequences of their involvement, given the amount of misrepresentation and abuse tha...

متن کامل

Public health genomics--public health goes personalized?

Correspondence: Angela Brand, Director, Institute for Public Health Genomics (IPHG), Cluster of Genetics and Cell Biology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 5, 6229 ES Maastricht, The Netherlands. e-mail: [email protected] . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . .. . . . . . . . . . . . . . . .. . . . ....

متن کامل

Lumiracoxib (Novartis).

Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.

متن کامل

Research fraud and public policy.

W e've been concerned recently about misconduct in scientific research. There's a lot to worry about: Some careers have been destroyed because the temptation to falsify data proved too great; others have been put on hold while irresponsible charges were allowed to dangle for years before being discredited. In the real instances of research misconduct we know about in biology and physics, the mo...

متن کامل

Fingolimod. Mitsubishi Pharma/Novartis.

Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Nature

سال: 1998

ISSN: 0028-0836,1476-4687

DOI: 10.1038/32734